Udai Veer Singh Sara

Udai Veer Singh Sara

Auto-generated profile, based on publicly available information

Udai Veer Singh Sara

Hygia Institute of Pharmaceutical Education and Research, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MYMohd Yasir
Mohd Yasir
Ameeduzzafar zafarAmeeduzzafar zafar
Ameeduzzafar zafar
KNKaveripakkam M. Noorulla
Kaveripakkam M. Noorulla
ATAbdurazak J. Tura
Abdurazak J. Tura
USUdai Vir Singh Sara
Udai Vir Singh Sara
DDDebesa D. Dalecha
Debesa D. Dalecha

30 June 2022 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
RGRamesh Kumar Gupta
Ramesh Kumar Gupta
SCSachin Chaudhary
Sachin Chaudhary
AEAbdel-Nasser El-Shorbagi
Abdel-Nasser El-Shorbagi
USUdaivir Singh Sara
Udaivir Singh Sara
PSprashant shukla
prashant shukla
PMP. N. Murthy
P. N. Murthy
At this moment, liver dysfunction is a major source of destruction, and its widespreadity is accentuated in the developed republics. The liver is an imperative organ of the body and is involved in metabolism and regulation. The large number of medications, toxins, and plant-derived products has been claimed to cause liver dysfunction, which is potentially life intimidating to humans. Currently, there is a shortfall in encouraging treatment for treating patients with liver dysfunction due to the nonexistence of empathy for gesturing offenders serviceable in the pathogenesis of liver toxicity. Hepatic dysfunction is manifested by hepatic karyopyknotic, eosinophilic or acidophilic cell plasm, followed by excessive steatosis, liver injury, and oxidative degradation of lipids that cause centrilobular necrosis in hepatocytes. Different signaling mechanism, like activation of Kupffer cells, NK cells, inflammatory mediators, and ROS are associated with the pathogenesis of liver dysfunction. A good empathy of chief mechanisms is prerequisite for the scheming of novel curative medications. Consequently, animal models are being developed to impressionist hepatic ailments. From the several decades, researchers are using distinctive animal models for discovering and understanding pathogenesis of hepatic ailments and associated abusiveness. This current review has been framed to discuss numerous new and traditional experimental models for hepatotoxicity studies. Numerous animal models have been evolved to evaluate the pathogenesis and develop drugs for hepatotoxicity. Experimental modes of hepatotoxicity are influential for invention of novel molecular signaling trails for the improvement of human health.

1 January 2026 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
ACAshwani Kumar Chaturvedi
Ashwani Kumar Chaturvedi
USUdai Veer Singh Sara
Udai Veer Singh Sara
Ram DayalRam Dayal
Ram Dayal
This study aims to optimize the process of extrusion spheronization for the development of rifaximin pellets and target them to the colon. Microcrystalline cellulose (MCC) is used to spheronizing aid in formulating pellets. MCC concentration, water content, spheronization speed, and time were optimized against roundness and % usable yield using Box-Behnken design. Coating levels of both the polymers were optimized using central composite design for drug release at 2, 4, 7, and 12 h at pH levels of 1.2, 6.8, 7.4, and 6.8 respectively. A gamma scintigraphy study helps in identifying transit pattern of coated pellets in GIT. Optimal conditions for rifaximin pellets with the desired pellet characteristics were identified as 34.19% MCC, 8.6% water, 1004 rpm, and 5.12 minutes. The observed values for drug release at 2, 4, 7, and 12 h at the aforesaid pH conditions were 0.17±0.00%, 3.08±0.13%, 39.01±1.17%, and 99.37±2.73%, respectively. This shows strong concordance between the observed and predicted values. The average durations for colon arrival, small intestine transit, and stomach emptying were 6.26±0.142 h, 5.72±0.408 h, and 0.70±0.265 h, respectively. This shows that the higher number of pellets reaches the colon in the desired time period. The study concluded with the development of optimized pellets and gamma scintigraphy confirms that the coating improves colonic rifaximin delivery.